Blueprint Medicines Corporation

BPMC Details

Blueprint Medicines Corporation (NASDAQ: BPMC) is a worldwide precision therapeutic firm dedicated to developing life-changing treatments for cancer and hematologic disorders. AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) are now distributed to US and European patients.

Latest News:

• Inducement Program: BPMC stated on October 05, 2021, that it issued non-qualified stock options to acquire 24,068 shares of its common stock and 12,033 restricted stock units (RSUs) to eight new employees, effective October 01, 2021, under its 2020 Inducement Plan. Previously, on September 03, 2021, it announced the issuance of non-qualified stock options to acquire 23,720 shares of its common stock and 11,858 RSUs to 12 new employees, with effect on September 01, 2021.
• Transfer of Responsibilities: On July 01, 2021, BPMC transferred specific duties relating to GAVRETO's sales to customers, pricing, and distribution matters in the US to its collaboration partner. As a result, no net product revenue from GAVRETO product sales was recorded in Q3FY21.

9MFY21 Results:

• Significant Decline in Topline: BPMC witnessed a sharp decrease of 90.38% in its total revenues to USD 73.06 million during 9MFY21 compared to USD 759.63 million during 9MFY20 due to nil net product revenue from GAVRETO product sales in Q3FY21 and a decline in total collaboration revenue during the period.
• Rise in Net Losses: The company recorded a net loss of USD 325.40 million during 9MFY21 vs. a net income of USD 399.55 million during 9MFY20.
• Adequate Balance Sheet: As of September 30, 2021, the company had cash and cash equivalents (including short-term investments) of USD 701.88 million and no outstanding debt.

Key Risks:

• Dependence on Third-Party Suppliers: The firm relies on third-party vendors to manufacture its pharmaceuticals and does not have its manufacturing facilities. This may jeopardize its capacity to satisfy product demand and, as a result, its overall performance.
• Patient Enrollment Risk: If the company encounters delays or difficulty in enrolling individuals in clinical trials, it may delay or block the receipt of essential regulatory licenses, deteriorating BPMC's financial conditions.

Outlook:

• FY21 Estimates: BPMC indicated on October 28, 2021, that it expected its FY21 revenues to be in the range of USD 170 – 180 million. This projection is based on increased product revenue and good collaborative execution, with numerous milestone payments scheduled for Q4FY21.

Valuation Methodology: EV/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

BPMC Daily Technical Chart (Source: REFINITIV)

Stock Recommendation:

BPMC's stock price has surged 32.14% in the past three months and is currently leaning towards the higher band of the 52-week range of USD 79.08 to USD 125.61. The stock is currently trading far above its 50 and 200 DMA levels, and its RSI Index is 73.03, indicating an overbought zone. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 106.75.

Considering the uptick in the stock price, we believe the decent fundamentals are sufficiently reflected at the current trading levels. Hence, we recommend a "Sell" rating on the stock at the current price of USD 113.63, up 0.72% as of November 02, 2021, at 1:01 PM ET.

* The reference data in this report has been partly sourced from REFINITIV.

*All forecasted figures and industry information have been taken from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.